$TSHA insider trading
Over the last 12 months, Taysha Gene Therapies insiders reported no purchases and 8 sales totaling $6.7M across SEC Form 4 filings. 38% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $6.7M 8 events
- Events · 12m
- 8 Form 4 filings, grouped
- Insiders · 12m
- 3 distinct reporters
- 10b5-1 share
- 38% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jul 10, 2026 | Nagendran SukumarPresident and Head of R&D · O·D | ▼ Sale | 200,000 | $6.24 | $1.2M | -17.6% | plan |
| Apr 10, 2026 | Nagendran SukumarPresident and Head of R&D · O·D | ▼ Sale | 200,000 | $4.46 | $892K | -15% | plan |
| Feb 4, 2026 | Alam KamranCHIEF FINANCIAL OFFICER · O | ▼ Sale | 1,655 | $4.52 | $7K | -0.1% | — |
| Jan 26, 2026 | Alam KamranCHIEF FINANCIAL OFFICER · O | ▼ Sale | 102,817 | $4.72 | $485K | -6.6% | 2 tranches |
| Jan 26, 2026 | Nagendran SukumarPresident and Head of R&D · O·D | ▼ Sale | 116,050 | $4.72 | $547K | -8.1% | 2 tranches |
| Jan 26, 2026 | Nolan Sean P.Chief Executive Officer · O·D | ▼ Sale | 178,101 | $4.72 | $840K | -5.8% | 2 tranches |
| Jan 12, 2026 | Nagendran SukumarPresident and Head of R&D · O·D | ▼ Sale | 200,000 | $4.71 | $942K | -16.6% | plan |
| Dec 1, 2025 | Nagendran SukumarPresident and Head of R&D · O·D | ▼ Sale | 370,172 | $4.58 | $1.7M | -26.9% | 2 tranches |
| Sep 10, 2025 | Nagendran SukumarPresident and Head of R&D · O·D | ▼ Sale | 200,000 | $3.23 | $646K | -16.6% | plan |
| Aug 21, 2025 | Nagendran SukumarPresident and Head of R&D · O·D | ▼ Sale | 57,054 | $2.85 | $163K | -4.7% | — |
| Aug 21, 2025 | Alam KamranCHIEF FINANCIAL OFFICER · O | ▼ Sale | 54,491 | $2.85 | $155K | -4.4% | — |
Every $TSHA filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Taysha Gene Therapies filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $TSHA feed.